We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

A Pilot Study of Piritrexim in Mycosis Fungoides

Herschel S. Zackheim, MD; Elizabeth A. Springer, MD; Patricia J. Brown, RN; Bruce U. Wintroub, MD; Neil J. Clendeninn, MD, PhD
Arch Dermatol. 1992;128(4):561-562. doi:10.1001/archderm.1992.01680140145023.
Text Size: A A A
Published online


To the Editor.—  Piritrexim (2,4-diamino-6[2,5-dimeth-oxybenzyl]-5-methylpyrido-[2,3-D] pyrimidine) (PTX) (BW-301U) is a novel lipid-soluble antifolate that has looked promising in clinical trials.1 It is as active as methotrexate as an inhibitor of dihydrofolate reductase. However, in contrast to methotrexate, it crosses membranes by passive diffusion and may be able to overcome cellular resistance to methotrexate due to folate transport mutations. Piritrexim, unlike methotrexate, is not polyglutamated and is potentially less hepatotoxic, since it is not stored in the liver as are methotrexate polyglutamates.2 Since methotrexate is effective in the treatment of cutaneous T-cell lymphoma,3 a trial of piritrexim in mycosis fungoides seemed reasonable. Unlike methotrexate, piritrexim has little anticancer effect when given as a single dose or over 24 hours. Therefore, the low-dose long-term administration schedule effective against neoplasms was used in this study.Nine patients (six women and three men; age range, 41 to 71 years) entered


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.